Immunotherapy
Immunotherapy is treatment that uses, restores, or redirects the immune system to help fight disease. In cancer care, it can help immune cells recognize and attack cancer, but it works only for some cancers and can cause distinctive immune-related side effects.
What immunotherapy is
Immunotherapy is a broad treatment category that works through the immune system. In cancer, the goal is often to help immune cells find, attack, or control cancer cells. Immunotherapy is not one drug or one method. It includes several approaches that act on different immune targets and work for different groups of patients.
Why cancer can evade immunity
The immune system can recognize abnormal cells, but cancer can escape in many ways. Tumors may hide antigens, weaken T-cell activity, create suppressive environments, or use immune checkpoints that normally prevent excessive immune damage. Immunotherapy tries to overcome some of these escape strategies.
Checkpoint inhibitors
Immune checkpoint inhibitors are among the best-known cancer immunotherapies. They block checkpoint proteins such as PD-1, PD-L1, or CTLA-4 that can restrain T-cell activity. In some cancers, releasing these brakes lets T cells attack tumor cells more effectively. The same immune activation can also cause inflammation in healthy tissues.
Cell therapies
Cell therapies use immune cells as the treatment itself. In CAR T-cell therapy, a patient's T cells are collected, modified in a laboratory to recognize a target, expanded, and returned to the body. Other T-cell transfer approaches may use tumor-infiltrating lymphocytes or selected immune cells. These therapies can be powerful but complex to manufacture and monitor.
Antibodies, vaccines, and immune modulators
Some monoclonal antibodies help immune cells recognize cancer, block growth signals, or carry toxic payloads to tumor cells. Cancer vaccines may try to train immunity against tumor-associated targets. Immune modulators can boost or reshape immune responses. These categories overlap, and not every antibody treatment is considered immunotherapy in the same way.
Who may benefit
Immunotherapy works very well for some patients and not at all for others. Benefit depends on cancer type, stage, prior treatments, immune health, tumor biology, biomarkers, and sometimes specific genetic or molecular features. Tests such as PD-L1 expression, mismatch repair status, microsatellite instability, or tumor mutation burden may help guide decisions in some settings.
Side effects
Because immunotherapy changes immune activity, side effects can look different from chemotherapy side effects. Immune-related side effects can affect the skin, gut, lungs, liver, kidneys, hormone glands, nerves, joints, blood, or heart. Some appear during treatment, while others appear later. Early reporting and careful management are important.
Combination treatment
Immunotherapy may be used alone or combined with chemotherapy, radiation therapy, targeted therapy, surgery, or another immunotherapy. Combinations can improve response in some cancers, but they can also add side effects and cost. Researchers study combinations to improve benefit while avoiding unnecessary treatment.
Limits and resistance
Immunotherapy is not a universal cancer cure. Some tumors do not attract immune attack, some lack useful targets, and some adapt after an initial response. Resistance can involve tumor evolution, immune suppression, antigen loss, poor T-cell entry into tumors, or changes in signaling pathways. Understanding resistance is a major research focus.
Why it matters
Immunotherapy matters because it changed cancer care from only attacking cancer cells directly toward also changing the relationship between tumors and the immune system. It has produced long-lasting responses in some cancers that were previously very difficult to treat. Its promise is real, but so are its limits, side effects, access challenges, and need for careful patient selection.